Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (296)	9/5/2007 11:21:04 PM
From: Clarksterh	Read Replies (2) \| Respond to of 332

Some interesting speculation (I was looking through the data vs other diabetes trials again). Combine the following facts: a) In other trials the amount of improvement vs baseline HbA1C is much larger for larger baseline HbA1C. And that is true in ARISE - but substantially less so than in other trials. b) Atherogenics has released data showing the placebo arm in the baseline HbA1C>8 (and even more so in HbA1C>9) actually improved their HbA1C. c) ARISE was a heart disease trial. Not a glycemic control trial. Result - a good bet that the placebo arm with baseline HbA1C>8 started a lot more additional diabetes drugs during the 1 year trial than the equivalent 1067 arm. Thereby shrinking the apparent benefit of 1067 in the HbA1C>8 subpopulation.